Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
epratuzumab
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Systemic Lupus Erythematosus |
Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
SL0002 Terminated |
NCT00113971 |
Hobbs et al. Ann Rheum Dis. 2011;70(Suppl 3):319, abs THU0425. European League Against Rheumatism (EULAR) 2011. May 25-28, 2011;London, UK. |
|||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus |
SL0003 Terminated |
NCT00111306 2005-000705-59 |
Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | |||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
SL0004 Terminated |
NCT00383214 2005-000706-31 |
Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | |||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus |
SL0005 Terminated |
NCT00382837 | ||||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Systemic Lupus Erythematosus |
SL0006 Completed |
NCT00383513 | Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322. | |||
| Systemic Lupus Erythematosus | Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease |
SL0007 Completed |
NCT00624351 2007-002566-35 |
Wallace et al. Ann Rheum Dis; 2014;73(1); 183-190. | |||
| Systemic Lupus Erythematosus | Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease |
SL0008 Completed |
NCT00660881 2007-002589-37 |
Wallace, D. J. et al. Arthritis Care Res (Hoboken);2016; 68;4;534-543 |
|||
| Systemic Lupus Erythematosus | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1) |
SL0009 Completed |
NCT01262365 2010-018563-41 |
LINK LINK |
Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 | ||
| Systemic Lupus Erythematosus | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) |
SL0010 Completed |
NCT01261793 2010-018565-26 |
LINK LINK |
Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 | ||
| Systemic Lupus Erythematosus | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4) |
SL0012 Completed |
NCT01408576 2010-020859-30 |
LINK LINK |
|||
| Systemic Lupus Erythematosus | Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) |
SL0026 Completed |
NCT01449071 |
Yamamoto et al. Ann Rheum Dis. 2014;73(suppl.2):526, abs. FRI0383. European League Against Rheumatism (EULAR) 2014. June 11-14, 2014;Paris, France. |
|||
| Systemic Lupus Erythematosus | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects |
SL0027 Completed |
NCT01534403 |